E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Respiratory Syncytial Virus |
Virus respiratorio sincitial |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory Syncytial Virus |
Virus respiratorio sincitial |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061603 |
E.1.2 | Term | Respiratory syncytial virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms. |
Evaluar la eficacia del rilematovir en comparación con el placebo con respecto al tiempo de resolución de los síntomas de la enfermedad del tracto respiratorio inferior por el virus sincitial respiratorio (VRS). |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the effect of rilematovir as compared to placebo: 1) with respect to the incidence of post baseline RSV-related complications; 2) on medical resource utilization (MRU) with respect to respiratory therapeutic interventions associated with RSV-related disease progression; 3) on MRU with respect to medically attended visits associated with RSV-related disease progression; 4) on the overall RSV-related disease progression; 5) on the clinical course of RSV infection; 6) Health-Related Quality of Life; 7) on MRU. - To evaluate the: 1) safety and tolerability of rilematovir; 2) the antiviral effect of rilematovir as measured by RSV viral load in bilateral nasal mid-turbinate swab samples by quantitative reverse transcription polymerase chain reaction assay; 3) emergence of mutations in the viral genome potentially associated with resistance to rilematovir; 4) pharmacokinetics of rilematovir. |
- Evaluar el efecto del rilematovir en comparación con el placebo: 1) con respecto a la incidencia de complicaciones relacionadas con el VRS después del inicio de la enfermedad; 2) en la utilización de recursos médicos (URM) con respecto a las intervenciones terapéuticas respiratorias asociadas con la progresión de la enfermedad relacionada con el VRS; 3) en la URM con respecto a las visitas con asistencia médica asociadas con la progresión de la enfermedad relacionada con el VRS; 4) en la progresión general de la enfermedad relacionada con el VRS; 5) en el curso clínico de la infección por el VRS; 6) en la calidad de vida relacionada con la salud; 7) en la URM. - Evaluar la: 1) la seguridad y la tolerabilidad de rilematovir Por favor, consultar el protocolo del estudio para ver la lista completa de objetivos secundarios. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. 18 to 85 years of age. 2. Presentation to the healthcare facility with symptoms suggestive of a diagnosis of acute RSV infection and have at least any 2 symptoms of LRTD. 3. Tested positive for RSV infection using a molecular-based diagnostic assay or on a respiratory tract sample. 4. Participants must have at least one high-risk condition that predispose them to RSV-related disease progression. 5. Randomized to study intervention treatment within 72 hours after onset of any of the RSV symptoms or worsening of pre-existing symptoms. 6. Not be hospitalized during screening. |
1. De 18 a 85 años de edad. 2. Acudir al centro de salud con síntomas que sugieran el diagnóstico de infección aguda por VRS y tener al menos 2 síntomas de EVRB. 3. Que hayan dado positivo en la prueba de infección por VRS mediante un ensayo de diagnóstico de base molecular o en una muestra del tracto respiratorio. 4. Los participantes deben tener al menos una condición de alto riesgo que los predisponga a la progresión de la enfermedad relacionada con el VRS. 5. Ser aleatorizados al tratamiento de intervención del estudio dentro de las 72 horas siguientes a la aparición de cualquiera de los síntomas del VRS o al empeoramiento de los síntomas preexistentes. 6. No estar hospitalizado durante la selección. |
|
E.4 | Principal exclusion criteria |
1. History of or concurrent disease or clinically significant findings during screening or medical history, physical examination, laboratory testing, vital signs, ECG recording, for which, in the opinion of the investigator, participation would not be in the best interest of the participant. 2. Any condition that could prevent, limit, or confound the protocol-specified assessments. 3. Known allergies, hypersensitivity, or intolerance to rilematovir or to any of the excipients of rilematovir or placebo formulation. 4. Participants who are considered by the investigator to be immunocompromised within the past 12 months, whether due to underlying medical condition or medical therapy. |
1. Antecedentes o enfermedades concurrentes o hallazgos clínicamente significativos durante la selección o la historia clínica, el examen físico, las pruebas de laboratorio, los signos vitales, el registro del ECG, para los que, en opinión del investigador, la participación no sería en el mejor interés del participante. 2. Cualquier condición que pueda impedir, limitar o confundir las evaluaciones especificadas en el protocolo. 3. Alergias conocidas, hipersensibilidad o intolerancia al rilematovir o a cualquiera de los excipientes de la formulación del rilematovir o del placebo. 4. Participantes que el investigador considere que están inmunocomprometidos en los últimos 12 meses, ya sea debido a una condición médica subyacente o a una terapia médica. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The time to resolution of RSV lower respiratory tract disease symptoms as assessed by using a Patient Reported Outcome Scale. |
El tiempo hasta la resolución de los síntomas de la enfermedad del tracto respiratorio inferior por el VRS, evaluado mediante una escala de resultados informada por el paciente. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Initiation of study treatment up to Day 35 |
Inicio del tratamiento del estudio hasta el día 35 |
|
E.5.2 | Secondary end point(s) |
Key secondary endpoints: - Proportion of participants with post-baseline complications. - Safety and tolerability, as assessed by adverse events (AEs), clinical laboratory testing, electrocardiograms (ECGs), physical examination, and vital signs. - RSV viral load and change from baseline over time. - Evaluation of Medical resource utilization throughout the study period. - Pharmacokinetic parameters of rilematovir. |
Criterios de valoración secundarios clave: - Proporción de participantes con complicaciones posteriores a la línea de base. - Seguridad y tolerabilidad, evaluadas por eventos adversos (EA), pruebas de laboratorio clínico, electrocardiogramas (ECG), examen físico y signos vitales. - La carga viral del VRS y el cambio en el tiempo respecto al momento de referencia. - Evaluación de la utilización de recursos médicos a lo largo del período de estudio. - Parámetros farmacocinéticos de rilematovir. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Throughout the study at specified timepoints. |
A lo largo del estudio en puntos de tiempo específicos. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
India |
Japan |
Mexico |
Russian Federation |
South Africa |
Taiwan |
Thailand |
Turkey |
Ukraine |
United States |
Bulgaria |
Germany |
Hungary |
Italy |
Poland |
Spain |
Sweden |
Switzerland |
United Kingdom |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 5 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 5 |